BioCentury | Aug 22, 2020
Translation in Brief

IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more

Synthetic switches aim T cells at cells expressing antigen combos David Baker’s team at University of Washington’s Institute for Protein Design published a study in Science showing its synthetic protein switches can direct T cells...
BioCentury | Mar 14, 2019
Financial News

TCG again backs Surrozen in $50M series B

Regenerative medicine company Surrozen raised a $50 Million series B round to move its optimized Wnt signaling mimetics into IND-enabling studies for an advanced liver disease yet to be determined. Surrozen Inc. (South San Francisco,...
BioCentury | Nov 28, 2018
Preclinical News

Placental organoid could improve preeclampsia therapies

...TGFβ) and SMAD family inhibitor, a wingless-type MMTV integration site family (WNT) activator, R-Spondin 1 (RSPO1...
BioCentury | Sep 21, 2018
Company News

Ahead of Ph Ib data, Celgene declines to exercise option to OncoMed bispecific

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Sept. 20 that partner Celgene Corp. (NASDAQ:CELG) will not exercise its option to license OncoMed's bispecific antibody navicixizumab (OMP-305B83) as a result of "strategic product portfolio considerations." The bispecific targeting...
BioCentury | Jan 12, 2018
Clinical News

OncoMed's rosmantuzumab lacks clinical benefit in Phase I for solid tumors

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said IV rosmantuzumab (OMP-131R10) every two weeks "failed to provide compelling evidence of clinical benefit" in an open-label, U.S. Phase Ia/Ib trial to treat advanced solid tumors. Data will be presented...
BioCentury | Oct 31, 2017
Distillery Therapeutics

Transplant

...RSPO1 and DEFA1 could help prevent GvHD-induced gut dysbiosis. In a mouse model of GvHD, RSPO1...
...and GvHD pathology. Next steps include testing RSPO1 in other dysbiosis-associated diseases. TARGET/MARKER/PATHWAY: R-Spondin 1 (RSPO1...
...24, 2017 doi:10.1084/jem.20170418 CONTACT: Takanori Teshima, Hokkaido University, Sapporo, Japan email: teshima@med.hokudai.ac.jp Michael Leviten Hokkaido University Defensin alpha 1 R-Spondin 1(RSPO1) Graft-versus-host...
BioCentury | Oct 27, 2017
Preclinical News

RSPO1 restores gut biome in GvHD

...Researchers at Hokkaido University (Sapporo, Japan) and colleagues found that R-Spondin 1 ( RSPO1 ) stimulates...
...of RSPO1-induced proliferation. In a stem cell transplant mouse model of dysbiosis, IV administration of RSPO1...
...The authors said that while both RSPO1 and alpha defensin prevented dysbiosis, the effects of RSPO1...
BioCentury | May 31, 2017
Distillery Techniques

Disease models

...small intestine with a cocktail of mouse epidermal growth factor (EGF) , noggin (NOG) and R-Spondin 1(RSPO1)...
...P450 Epidermal growth factor (EGF) Liver X receptor (LXR) Noggin (NOG) Peroxisome proliferation activated receptor (PPAR) alpha Pregnane X receptor (PXR) R-Spondin 1(RSPO1) UDP...
BioCentury | Jan 20, 2017
Clinical News

OMP-131R10: Interim Ph Ia/Ib data

Interim data from 11 evaluable patients with advanced solid tumors in the Phase Ia portion of an open-label, dose-escalation, U.S. Phase Ia/Ib trial showed that 2.5-15 mg/kg doses of IV OMP-13R10 every 2 weeks led...
BioCentury | Feb 4, 2016
Distillery Therapeutics

Therapeutics: R-Spondin 1 (RSPO1); RSPO2; RSPO3

...inhibiting RSPO1 , RSPO2 or RSPO3 could help treat cancers. In primary tumor patient samples, RSPO1...
...expressed in ovarian and lung tumors. In patient-derived xenograft mouse models of ovarian cancer, an anti-RSPO1...
...TOP1) inhibitor irinotecan is marketed to treat colon, pancreatic and other cancers. TARGET/MARKER/PATHWAY: R-Spondin 1 (RSPO1...
Items per page:
1 - 10 of 18